

**IN-VIVO ENERGY DEPLETING STRATEGIES FOR KILLING
DRUG-RESISTANT CANCER CELLS**

ABSTRACT OF THE INVENTION

5 This invention also provides a method for treating a cancer
subject comprising administering to the subject a combination
of ATP-depleting agents at concentrations which deplete the
ATP level to, or close to, at least 15% of normal in cancer
cells wherein at least one of the ATP-depleting agents is a
10 mitochondrial ATP-inhibitor, a methylthioadenosine
phosphorylase inhibitor or an inhibitor of De Novo purine
synthesis other than 6-Methylmercaptapurine riboside, wherein
said composition produces a substantially better effect than a
composition without at least one of the ATP-depleting agents:
15 a mitochondrial ATP-inhibitor, a glycolytic inhibitor, a
methylthioadenosine phosphorylase inhibitor and an inhibitor
of De Novo purine synthesis other than 6-Methylmercaptapurine
riboside.